---
title: "LRMR: Nomlabofusp shows sustained FXN increases, clinical benefit, and advances toward accelerated approval"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291130146.md"
description: "FDA alignment supports a rolling BLA submission for nomlabofusp in Friedreich's ataxia, with positive open-label data showing sustained FXN increases and clinical improvements over 1–18 months. Safety profile remains consistent, and Phase 3 dosing is planned for Q3 2026.Original document: Larimar Therapeutics, Inc. [LRMR] Press release — Jun. 29 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-06-29T10:36:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291130146.md)
  - [en](https://longbridge.com/en/news/291130146.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291130146.md)
---

# LRMR: Nomlabofusp shows sustained FXN increases, clinical benefit, and advances toward accelerated approval

FDA alignment supports a rolling BLA submission for nomlabofusp in Friedreich's ataxia, with positive open-label data showing sustained FXN increases and clinical improvements over 1–18 months. Safety profile remains consistent, and Phase 3 dosing is planned for Q3 2026.

Original document: Larimar Therapeutics, Inc. \[LRMR\] Press release — Jun. 29 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [LRMR.US](https://longbridge.com/en/quote/LRMR.US.md)

## Related News & Research

- [20:11 ETINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR](https://longbridge.com/en/news/291473664.md)
- [Larimar Stock Slides 15% Despite FDA Backing Rolling Submission For Rare Disease Drug](https://longbridge.com/en/news/291162279.md)
- [Sam Altman said AI hasn't led to 4-hour workweeks because people are competitive](https://longbridge.com/en/news/293883472.md)
- [Alvotech announces successful closure of FDA inspection of manufacturing facility | ALVO Stock News](https://longbridge.com/en/news/294216022.md)
- [Imunon says Phase 3 OVATION 3 ovarian cancer trial enrollment outpaces plan](https://longbridge.com/en/news/294371031.md)